Routine clinical use is accelerating, driven by advanced image quality, expanding clinical utility, and increasingly diverse use cases across hospital and office settings.
GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the achievement of scan volume milestones in key hospitals and neurology clinics, demonstrating accelerating clinical utilization and adoption of the Swoop® system throughout the United States.
The increasing clinical use of the Swoop® system is driven by several factors: enhanced clinical utility from improved image quality, growing evidence of its economic value, and expanding adoption across new care settings, including neurology clinics and the emergency department (ED). The most successful Swoop® system programs are driven by visionary healthcare leaders who are passionate about addressing the challenges of MRI availability and recognize the clinical and economic value of portable MRI in expanding patient access to imaging.
Jennifer Villa Frabizzio, MD, Chief of Neuroradiology at Jefferson Abington Hospital, who has used the Swoop® system for over three years, commented, “We are excited to have surpassed one thousand Swoop® system scans, making us the highest volume center in the United States. Since we have such a robust Swoop® system program, we decided to evaluate the impact to our hospital, which was recently published in a peer-reviewed journal. We were impressed to find that increasing access to imaging with the Swoop® system not only improved patient care but also delivered meaningful cost savings, significantly reduced MRI wait times in the ICU and ED, and improved patient progression throughout the hospital. Recently, we have also started using the Swoop® system for outpatient brain MRI to reduce wait times for patients at outpatient clinics.” As healthcare systems face mounting pressure to improve both efficiency and quality of care, Jefferson Abington’s experience provides compelling evidence that portable brain MRI offers strong clinical utility and a favorable health economic profile, particularly at scale.
CHRISTUS Mother Frances, one of the first sites to adopt the next-generation Swoop® system, crossed the 500-scan milestone in just nine months, driven by integrating the Swoop® system into a scalable stroke program. As adoption continues to accelerate, Chief Medical Officer at the center, Mark Anderson, MD, shared, “The Swoop® system has had such a big impact improving patient care and hospital efficiency with our stroke patients in the main hospital ED, we purchased an additional system to place in a satellite ED to help triage stroke patients – enabling faster patient care and avoiding unnecessary admissions and transport costs. We are also pioneering use in the operating room, becoming the first in the United States to conduct transsphenoidal tumor resection using the Swoop® system pre- and post-operatively to confirm surgical success.”
Clinical use of the Swoop® system is accelerating in neurology offices, where it has quickly become a valuable extension of the diagnostic workflow since its introduction in mid-2025. Neurology of Central Florida has already exceeded 500 in-office MRI scans, demonstrating how point-of-care imaging enables neurologists to complete diagnostic evaluations within their own practice. As Alicia Cabrera, MD, noted, “The Swoop® System is an excellent tool to expedite the diagnostic process—it’s the missing link we didn’t have before. Patients used to wait weeks for imaging and results; now we can often get answers within 24 to 72 hours, allowing faster decisions and helping avoid unnecessary emergency room visits.” The Swoop® system provides a more comfortable and convenient patient experience, supported by NEURO PMR findings showing a 4:1 patient preference for portable MRI. It is now routinely used for outpatient applications, including headache, dementia, multiple sclerosis surveillance, and emerging brain health assessments.
“The experiences at Jefferson Abington, CHRISTUS Mother Frances, and Neurology of Central Florida reflect what we hear consistently from clinicians—timely access to MRI remains a meaningful challenge and portable MRI is helping address that need,” said Maria Sainz, President and CEO of Hyperfine. “By eliminating the barriers that have long defined conventional MRI—wait times, technologist shortages, cost, and immobility—the Swoop® system enables faster decision-making across the hospital and beyond. At Hyperfine, we have redefined what MRI delivery looks like, and we remain committed to supporting brain health by making high-quality imaging available to more patients across more care settings.”
Hear more from these hospital centers in our recent webinar on how portable MRI is transforming stroke care.
For more information about the Swoop® system, please visit HyperfineMRI.com.
About the Swoop® Portable MRI Systems
The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com.
Hyperfine, the Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy, including its entrance into new markets. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future ; the inability of the Company to progress on product advancements and improvements ; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; existing and potential future National Institutes of Health funding pressures; existing and potential future effects from U.S. export controls and tariffs; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Contacts
Media Contact
Devin Zell
Hyperfine
[email protected]
Investor Contact
Webb Campbell
Gilmartin Group LLC
[email protected]
